BioElectronics' ActiPatch Reduces Muscle Soreness in Runners

USA - English

• India - English

FREDERICK, Md., May 7, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the completion of a randomized, controlled trial on delayed muscle onset soreness using BIEL's ActiPatch® product.  ActiPatch uses pulsed electromagnetic field therapy to reduce pain, inflammation, and promote the healing of injured tissue.

A double blind, randomized, placebo controlled trial on delayed onset muscle soreness after marathon running found that ActiPatch® significantly reduces muscle soreness in the thighs in  runners, in the days after the completion of a marathon, compared to runners who used a placebo device. There was also a strong trend to increased running activity post marathon, which was significant on the first day after the marathon. This research study is now under peer review for publication, and the results will also be presented at EFORT (European Federation of National Associations of Orthopaedics and Traumatology) conference in Berlin, May 2012. The principle investigator leading the research was Dr. Rasmussen, Associate Professor Director of Research, Aarhus University Hospital, Aalborg Hospital, Denmark.

This study also confirms the results in the previous US muscle onset soreness study wherein ActiPatch® showed superior, and statistically significant pain relief compared to the OTC drug, acetaminophen. It has been forwarded to the FDA to support the Company's ActiPatch® application for relief of musculoskeletal pain. 

"We are delighted about the completion of this second randomized control trial on delayed muscle onset soreness," said Ian Rawe, Ph.D., BioElectronics Director of Clinical Research. "There are currently no interventions that can effectively alleviate muscle soreness, and certainly none that allow for quicker return to physical activity. These results suggest that BioElectronics' ActiPatch® device has the potential to be widely used in sports applications, not just for injury recovery but also injury prevention and improved performance. The exposure of these results and our technology at the EFORT conference, presented by a respected researcher, will be extremely beneficial, and in due course will attract more research in this interesting field."

"The fact that these research initiatives have been independently undertaken show that our technology is becoming widely accepted by the medical community," said Andrew Whelan, CEO.

About BioElectronics Corporation

BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:  E & E Communications
Paul Knopick
(949) 707-5365

SOURCE BioElectronics Corporation